Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic expanded fetal mesenchymal stem cells
- Development stage
- Phase 2
- Lead developer
- Karolinska Institutet
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic expanded fetal mesenchymal stem cells are an investigational cell therapy product developed by Karolinska Institutet for the treatment of severe forms of osteogenesis imperfecta (OI). These cells are derived from fetal liver tissue and expanded in vitro to create a therapeutic population of mesenchymal stem cells. The therapy is designed to be administered either prenatally (in utero) or postnatally. Once transplanted, these healthy donor cells are intended to engraft into the patient's bone, differentiate into osteoblasts, and produce functional type I collagen. This process aims to supplement or replace the defective collagen produced by the patient's own cells, thereby improving bone mineral density, increasing bone strength, and reducing the frequency of fractures. The development of this therapy is a central component of the international BOOSTB4 (Boost Brittle Bones Before Birth) consortium.
- Other names
- fetal mesenchymal stem cellsfetal liver-derived mesenchymal stem cellsallogeneic fetal mesenchymal stem cells
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on allogeneic expanded fetal mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic expanded fetal mesenchymal stem cells.